Alleviating Inflammatory and Neuroinflammatory Diseases

NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.

latest news
Jun 25, 2018
NodThera secures £28 million ($40 million) Series A Financing
  • NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic...
about us

NLRP3 inflammasome inhibitors represent a new generation of medicines for the treatment of many debilitating chronic conditions

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation. NodThera was seed funded by Epidarex Capital based on research from Selvita.

Inflammation is a protective immune response to noxious stimuli; however, improper activation of the innate immune system can lead to chronic inflammation and disease.

Inflammasomes are key components of the inflammatory response. These multi-protein complexes, when inappropriately activated, are implicated in a wide range of diseases including arthritis, atherosclerosis, Alzheimer’s disease, diabetes and certain cancers, the prevalence of which are all increasing dramatically. NodThera is initially targeting the NLRP3 inflammasome with small molecule inhibitors and is building a pipeline of NLRP3 inflammasome inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.

about us

NLRP3 inflammasome inhibitors represent a new generation of medicines for the treatment of many debilitating chronic conditions

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation. NodThera was seed funded by Epidarex Capital based on research from Selvita.

Inflammation is a protective immune response to noxious stimuli; however, improper activation of the innate immune system can lead to chronic inflammation and disease.

Inflammasomes are key components of the inflammatory response. These multi-protein complexes, when inappropriately activated, are implicated in a wide range of diseases including arthritis, atherosclerosis, Alzheimer’s disease, diabetes and certain cancers, the prevalence of which are all increasing dramatically. NodThera is initially targeting the NLRP3 inflammasome with small molecule inhibitors and is building a pipeline of NLRP3 inflammasome inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.

management team
board
investors
contact us
Address

NodThera Limited
Suite 8, The Mansion
Chesterford Research Park
Little Chesterford
CB10 1XL, UK
Phone

+44 (0) 7928 555460
(main office)

Email

Media enquiries – nodthera@consilium-comms.com
Job enquiries – jobs@nodthera.com
Business enquiries – info@nodthera.com

close bio
join us

Based in Cambridge UK and with offices in Seattle WA and Boston MA, NodThera is a global business.

As we push the frontiers of inflammation research we are looking to work with experts in the fields of immunology and drug discovery.

 

CURRENT VACANCIES

Senior Scientist, Medicinal Chemistry

Location: Chesterford Research Park, near Cambridge, UK

Full time, permanent

As a result of an ongoing expansion, NodThera is looking for an exceptional Medicinal Chemist to join a small but growing team.  The successful candidate will make an immediate contribution to the design of compounds and will support other activities associated with advancing the portfolio of potential drug candidates.  This is a tremendous opportunity to join a well-funded biotechnology company operating in a cutting-edge area of research at an important stage in our expansion.

Duties:

  • Analyse and interpret scientific data from multiple sources, using resulting information to guide the design of future targets and experiments
  • Perform literature and patent searches
  • Draft experimental patent procedures
  • Provide support to synthetic chemistry CROs; ensure smooth progression of targets, troubleshoot reactions and advise on synthetic routes
  • Support other outsourced activities
  • Compile data for and give presentations on Medicinal Chemistry both internally and externally as appropriate   
  • Continually develop scientific knowledge as appropriate to the role and the area of research


Skills and experience required:

  • Relevant educational qualifications (BSc/MSc/PhD in Chemistry, Medicinal Chemistry or a related subject)
  • Minimum five years’ experience in small molecule drug discovery gained in an industrial setting, supported by a track record of publications, patents and presentations
  • Detailed understanding of contemporary small molecule Medicinal Chemistry principles, DMPK, ADMET and pharmacology
  • Skilled in data and SAR analysis and interpretation
  • Track record of significant contribution toward the design of drug-like molecules
  • Excellent interpersonal and communication skills, high attention to detail
  • Strong desire to work in a fast-paced biotech environment, a willingness to be adaptable to the potential of changing roles and responsibilities

To apply for the role please send the following to jobs@nodthera.com

  • CV
  • Covering letter
  • Confirmation of your eligibility to work in the UK (independently of employer sponsorship)

Deadline for application – 7th September